Prostate Specific Antigen News and Research

RSS

Severe COVID-19 raises alarm for undiagnosed cancer

Severe SARS-CoV-2 infection is associated with a 1.31 higher risk of being diagnosed with cancer following hospital discharge, particularly renal, hematological, colon, and lung cancers, suggesting a potential link between the infection and undiagnosed cancer.

1 Jun 2023

Accounting for genetic factors can improve accuracy of prostate cancer screening

The accuracy of prostate-specific antigen (PSA) screening for prostate cancer can be improved by accounting for genetic factors that cause changes in PSA levels that are not associated with cancer, according to a multi-center study led by UC San Francisco and Stanford University.

1 Jun 2023

Phase 3 studies for rectal, brain, and kidney cancers to be presented by Dana-Farber researchers at ASCO 2023

Several phase 3 studies conducted by researchers from Dana-Farber Cancer Institute show promising results for patients with rectal, brain, and kidney cancers. The results of these studies, along with dozens of others led by Dana-Farber researchers, will be presented at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

26 May 2023

Shared decision policies lead to high rates of PSA testing and inequity with minimal benefit

Most high income countries, including the UK, do not have a national prostate cancer screening programme, but instead allow men without symptoms to get a prostate-specific antigen (PSA) test if they wish, after talking to their doctor.

18 May 2023

UC San Diego Health offers a new minimally invasive biopsy procedure to detect prostate cancer

UC San Diego Health is the first health system in San Diego County to offer a new minimally invasive prostate biopsy procedure that reduces the risk of infection, improves imaging for accuracy and may increase cancer detection in a clinic setting.

25 Apr 2023

Phase 2 study shows safety and efficacy of new drug in men with high-risk prostate cancers

A new drug, a monoclonal antibody known as enoblituzumab, is safe in men with aggressive prostate cancer and may induce clinical activity against cancer throughout the body, according to a phase 2 study led by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy.

6 Apr 2023

Why men should eat more plants: the effect of mediterranean plant-forward diets on health

Researchers performed a systematic review of existing data to investigate whether plant-forward (PF) diets could improve male health.

29 Mar 2023

Researchers estimate the environmental impacts of prostate MRI and biopsy

A Yale-led study examines the potential environmental benefits of more carefully selecting patients for prostate biopsy in a way that can also spare low-yield and potentially harmful procedures.

22 Feb 2023

Enhanced prediction of prostate cancer recurrence using machine learning model

Predicting the course of prostate cancer is challenging because only a fraction of prostate cancer patients experience recurrence after radical prostatectomy or radiation therapy.

14 Feb 2023

Declining PSA levels predict improved survival rates in men with non-metastatic castration-resistant prostate cancer

Declines in prostate-specific antigen (PSA) level after treatment with the next-generation androgen receptor inhibitor drug enzalutamide predict improved survival rates in men with non-metastatic castration-resistant prostate cancer (nmCRPC), reports The Journal of Urology, an Official Journal of the American Urological Association.

10 Feb 2023

New blood test can detect prostate cancer with greater accuracy than current methods

Researchers at the University of East Anglia have helped develop a new blood test to detect prostate cancer with greater accuracy than current methods.

8 Feb 2023

New nanotechnology-based test can detect and profile prostate cancers even in microscopic amounts

Cedars-Sinai Cancer investigators have developed a new nanotechnology-based test that can detect and profile prostate cancers-;even in microscopic amounts.

2 Feb 2023

Hormonal therapy may aid in reducing progression of early-stage prostate cancer during active surveillance

For men with early-stage prostate cancer being managed by active surveillance, adding the hormonal agent apalutamide may lower the rate of positive biopsies during follow-up, suggests a preliminary clinical trial in The Journal of Urology, an Official Journal of the American Urological Association.

11 Jan 2023

PSMA PET/MRI can successfully determine the risk of prostate cancer recurrence

In men recently diagnosed with intermediate or high-grade prostate cancer, prostate specific membrane antigen (PSMA) PET/MRI can successfully determine whether their cancer is likely to return within two years of a prostatectomy.

6 Jan 2023

Study shows the prevalence of low-value prostate cancer screening in primary care clinics

Prostate cancer is the second-leading cause of cancer death in men with more than 34,000 deaths in the U.S. each year, according to the American Cancer Society.

4 Jan 2023

Rising Medicare costs linked to increased use of new prostate cancer therapies

Medicare costs for treatment of metastatic prostate cancer have risen sharply within the last 15 years – reflecting increased use of new medications under Medicare Part D, reports a study in Urology Practice, an Official Journal of the American Urological Association.

20 Dec 2022

Cambridge scientists develop a comprehensive tool for predicting individual's risk of prostate cancer

Cambridge scientists have created a comprehensive tool for predicting an individual's risk of developing prostate cancer, which they say could help ensure that those men at greatest risk will receive the appropriate testing while reducing unnecessary – and potentially invasive – testing for those at very low risk.

12 Dec 2022

Study identifies risk factors that increase Black men's susceptibility to early-onset prostate cancer

A family history of cancer and genetic variants that might be inherited appear to be important risk factors for Black men diagnosed with early-onset prostate cancer, a study involving Duke Health researchers has found.

29 Nov 2022

Study shows benefits of metastasis-directed therapy without ADT for oligorecurrent prostate cancer

For patients with solitary metastases from prostate cancer, an approach called metastasis-directed therapy (MDT) – focused treatment using surgery or radiation therapy, without androgen deprivation therapy (ADT) – can slow the time to cancer progression, reports a study in The Journal of Urology, an Official Journal of the American Urological Association

10 Nov 2022

Polygenic hazard score could be effective for predicting genetic risk of lethal prostate cancer

Tapping into the Million Veteran Program, an ongoing national research effort to learn how genes, lifestyle and military exposures affect the health of participants, researchers at University of California San Diego School of Medicine and the VA San Diego Healthcare System, with colleagues elsewhere, report that a polygenic hazard score based on 290 genetic variants could be an effective tool for predicting genetic risk of lethal prostate cancer.

31 Oct 2022